Booster Therapeutics emerges from stealth

Berlin, Germany-based Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing led by noted life sciences investors Apollo Health Ventures and Novo Holdings.

Novo Holdings said in its own press release on the development that it will play a central role in helping to further build Booster in its next phase of growth, bringing hands-on operational expertise, strategic guidance and helping the company access a larger network of talent. Novo Holdings will further leverage the expertise in its group of entrepreneurs-in-residence, as well as the Seed Lab wet-lab capabilities in Copenhagen, Denmark.

Booster was founded by Dr Diogo Feleciano, Prof Dr Darci Trader, and Apollo Health Ventures, emerging from Apollo's company creation investment strategy. The company is developing small molecule therapeutics that boost the innate activity of proteasomes to restore the body’s ability to remove a wide range of disease-causing proteins.